Interaksi Olmesartan, amlodipin, dan hidroklorotiazid

Do not co-administer aliskiren with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet in patients with diabetes [ See Drug Interactions (7.2)]. (label Olmesartan, amlodipin, dan hidroklorotiazid, Kontraindikasi)

Hyperkalemia occurs commonly (about 10%) when amiloride is used without a kaliuretic diuretic. (label Amilorid, Peringatan kotak hitam)

Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes. (label Amlodipin dan benazepril, Kontraindikasi)

The risk of torsade de pointes is related to the extent of QTc prolongation, concomitant administration of QTc prolonging drugs, a history of torsade de pointes, pre-existing QTc interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalemia or hypomagnesemia. (label Arsen trioksida, Peringatan dan perhatian)

CONTRAINDICATIONS All diuretics, including ethacrynic acid, are contraindicated in anuria. (label Asam etakrinat, Kontraindikasi)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (label Olmesartan, amlodipin, dan hidroklorotiazid, Kontraindikasi)

Do not coadminister aliskiren with angiotensin receptor blockers, ACE inhibitors, including Lotensin in patients with diabetes [see Drug Interactions (7.4) ] . (label Benazepril, Kontraindikasi)

Lotensin HCT is also contraindicated in patients who are hypersensitive to benazepril, to any other ACE inhibitor, to hydrochlorothiazide, or to other sulfonamide-derived drugs. (label Benazepril dan hidroklorotiazid, Kontraindikasi)

Literature reports suggest that oral calcium antagonists may be used in combination with beta-adrenergic blocking agents when heart function is normal, but should be avoided in patients with impaired cardiac function. (label Betaksolol, Interaksi obat)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (label Olmesartan, amlodipin, dan hidroklorotiazid, Kontraindikasi)

WARNING Bumetanide is a potent diuretic which, if given in excessive amounts, can lead to a profound diuresis with water and electrolyte depletion. (label Bumetanid, Peringatan kotak hitam)

The concomitant use of RYANODEX and calcium channel blockers is not recommended during the treatment of malignant hyperthermia. (label Dantrolen, Interaksi obat)

CONTRAINDICATIONS PROGLYCEM is contraindicated in patients with: Functional hypoglycemia Hypersensitivity to diazoxide, any of the excipients in PROGLYCEM, or other thiazides (label Diazoksid, Kontraindikasi)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (label Olmesartan, amlodipin, dan hidroklorotiazid, Kontraindikasi)

The concomitant use of hydrochlorothiazide (alone or in combinations such as with triamterene) with dofetilide is contraindicated (see PRECAUTIONS, Drug-Drug Interactions ) because this has been shown to significantly increase dofetilide plasma concentrations and QT interval prolongation. (label Dofetilid, Kontraindikasi)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (label Olmesartan, amlodipin, dan hidroklorotiazid, Kontraindikasi)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (label Olmesartan, amlodipin, dan hidroklorotiazid, Kontraindikasi)

Droperidol should be administered with extreme caution to patients who may be at risk for development of prolonged QT syndrome (e.g., congestive heart failure, bradycardia, use of a diuretic, cardiac hypertrophy, hypokalemia, hypomagnesemia, or administration of other drugs known to increase the QT interval). (label Droperidol, Peringatan kotak hitam)

…sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include those with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Enalaprilat, Peringatan)

…• serum creatinine > 2.0 mg/dL in males or >1.8 mg/dL in females, • creatinine clearance < 50 mL/min, or • concomitant administration of potassium supplements or potassium-sparing diuretics (e.g., amiloride, spironolactone, or triamterene) [see Warnings and Precautions (5.1) , Adverse Reactions (6.2) , Drug Interactions (7) , and Clinical Pharmacology (12.3)… (label Eplerenon, Kontraindikasi)

…of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (label Eptifibatid, Kontraindikasi)

IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and BREVIBLOC in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving BREVIBLOC and intravenous verapamil. (label Esmolol, Kontraindikasi)

Table 2: Oral drugs that can be administered concomitantly with Ferric Citrate Tablets Amlodipine Aspirin Atorvastatin Calcitriol Clopidogrel Digoxin Diltiazem Doxercalciferol Enalapril Fluvastatin Glimepiride Levofloxacin Losartan Metoprolol Pravastatin Propranolol Sitagliptin Warfarin Oral drugs that have to be separated from Ferric Citrate Tablets and meals… (label Feri sitrat, Interaksi obat)

Because the use of diuretics can accentuate the diminished intravascular volume, diuretics should be avoided except in the late phase of resolution as described below. (label Folitropin, Peringatan dan perhatian)

The concurrent use of gentamicin with potent diuretics, such as ethacrynic acid or furosemide, should be avoided, since certain diuretics by themselves may cause ototoxicity. (label Gentamisin, Peringatan kotak hitam)

Avoid diuretics or laxatives in patients with diarrhea. (label Irinotekan, Peringatan dan perhatian)

Calcium Channel Blockers Felodipine Nisoldipine Contraindicated during and 2 weeks after TOLSURA treatment. (label Itrakonazol, Interaksi obat)

Obat-obat ini mengurangi ekskresi kalium; menambahkan suplemen kalium atau garam pengganti dapat menyebabkan hiperkalemia, yang memengaruhi irama jantung. (NIH Office of Dietary Supplements, Potassium)

The following drug interactions may occur with potassium citrate: Potassium-sparing diuretics: concomitant administration should be avoided since the simultaneous administration of these agents can produce severe hyperkalemia (7.1) (label Kalium sitrat, Interaksi obat)

• Calcium Channel Blockers: Avoid concomitant use with Calcium Chloride Injection. (label Kalsium klorida, Interaksi obat)

…with colchicine; markedly increased transaminases with lomitapide; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; hypoglycemia and cardiac arrhythmias (e.g., torsades de pointes) with disopyramide; and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine). (label Klaritromisin, Peringatan dan perhatian)

Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (label Klozapin, Peringatan kotak hitam)

Because the use of diuretics can accentuate the diminished intravascular volume, avoid diuretics except in the late phase of resolution. (label Koriogonadotropin alfa, Peringatan)

…sometimes associated with oliguria and/or progressive azotemia, and rarely with acute renal failure and/or death, include patients with the following conditions or characteristics: heart failure, hyponatremia, high dose diuretic therapy, recent intensive diuresis or increase in diuretic dose, renal dialysis, or severe volume and/or salt depletion of any etiology. (label Kuinapril, Peringatan)

IV administration of non-dihydropyridine calcium-channel antagonists (e.g., verapamil) Hypersensitivity reactions, including anaphylaxis, to labetalol Bronchial asthma ( 4 ) (label Labetalol, Kontraindikasi)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (label Olmesartan, amlodipin, dan hidroklorotiazid, Kontraindikasi)

Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (label Metolazon, Peringatan)

Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (label Minoksidil, Peringatan kotak hitam)

Sodium bicarbonate injection is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction and in patients receiving diuretics known to produce a hypochloremic alkalosis. (label Natrium bikarbonat, Kontraindikasi)

The concurrent use of neomycin with potent diuretics such as ethacrynic acid or furosemide should be avoided, since certain diuretics by themselves may cause ototoxicity. (label Neomisin, Peringatan kotak hitam)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (label Olmesartan, amlodipin, dan hidroklorotiazid, Kontraindikasi)

Potassium-Sparing Diuretics Cyclosporine should not be used with potassium-sparing diuretics because hyperkalemia can occur. (label Siklosporin, Interaksi obat)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (label Olmesartan, amlodipin, dan hidroklorotiazid, Kontraindikasi)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (label Olmesartan, amlodipin, dan hidroklorotiazid, Kontraindikasi)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (label Olmesartan, amlodipin, dan hidroklorotiazid, Kontraindikasi)

…coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (label Tadalafil, Peringatan dan perhatian)

Because of the hydrochlorothiazide component, olmesartan medoxomil, amlodipine and hydrochlorothiazide tablet is contraindicated in patients with anuria, hypersensitivity to any component, or hypersensitivity to other sulfonamide-derived drugs. (label Olmesartan, amlodipin, dan hidroklorotiazid, Kontraindikasi)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (label Alfuzosin, Peringatan dan perhatian)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Hypersensitivity reactions to allopurinol tablets may be increased in patients with decreased kidney function receiving thiazide diuretics and allopurinol tablets concurrently. (label Alopurinol, Peringatan dan perhatian)

Ethacrynic Acid, Furosemide, Urea, or Mannitol Some diuretics can enhance aminoglycoside toxicity by altering aminoglycoside concentrations in serum and tissue. (label Amikasin, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Impact of Other Drugs on Amlodipine CYP3A Inhibitors Co-administration with CYP3A inhibitors (moderate and strong) results in increased systemic exposure to amlodipine and may require dose reduction. (label Amlodipin, Interaksi obat)

• Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher amlodipine and atorvastatin dosage. (label Amlodipin dan atorvastatin, Peringatan dan perhatian)

In patients with an activated renin-angiotensin system, such as volume and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil . (label Amlodipin dan olmesartan, Peringatan dan perhatian)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur in patients receiving angiotensin receptor blockers. (label Amlodipin dan valsartan, Peringatan dan perhatian)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (label Arformoterol, Interaksi obat)

Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (label Aripiprazol, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Elderly patients and those receiving diuretic therapy are at increased risk of acute renal failure. (label Asam zoledronat, Peringatan dan perhatian)

Although β-blockers should be avoided in overt cardiac failure, acebutolol can be used with caution in patients with a history of heart failure who are controlled with digitalis and/or diuretics. (label Asebutolol, Peringatan)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (label Asenapin, Peringatan dan perhatian)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

(See DOSAGE AND ADMINISTRATION . ) Concomitant Use of Calcium Channel Blockers Bradycardia and heart block can occur and the left ventricular end diastolic pressure can rise when beta-blockers are administered with verapamil or diltiazem. (label Atenolol, Peringatan)

Because of its relative beta 1 -selectivity, however, atenolol and chlorthalidone may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. (label Atenolol dan klortalidon, Peringatan)

Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (label Atomoksetin, Interaksi obat)

CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (label Avanafil, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with azilsartan medoxomil. (label Azilsartan, Peringatan dan perhatian)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Diuretics Clinical Impact : Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Beladona dan opium, Interaksi obat)

Amphetamines may decrease the hypotensive effect of antihypertensives. (label Benzfetamin, Interaksi obat)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (label Bisoprolol, Peringatan)

Because of the relative beta 1 -selectivity of bisoprolol fumarate, bisoprolol fumarate and hydrochlorothiazide tablets may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (label Bisoprolol dan hidroklorotiazid, Peringatan)

Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (label Bortezomib, Peringatan dan perhatian)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (label Brekspiprazol, Peringatan dan perhatian)

Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (label Brimonidin, Interaksi obat)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (label Brimonidin dan timolol, Interaksi obat)

Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (label Bromfeniramin, pseudoefedrin, dan dekstrometorfan, Interaksi obat)

Use caution in patients taking antihypertensive medications. (label Bromokriptin, Peringatan dan perhatian)

Diuretics: Use with caution. (label Budesonid dan formoterol, Interaksi obat)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Buprenorfin, Interaksi obat)

Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Buprenorfin dan nalokson, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Butalbital, parasetamol, kafein, dan kodein, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (label Dekslansoprazol, Peringatan dan perhatian)

• Antihypertensive Drugs: Monitor blood pressure. (label Deksmetilfenidat, Interaksi obat)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with NORPRAMIN. (label Desipramin, Peringatan)

…Hyponatremia Concomitant administration of DESMODA with other drugs that may increase the risk of water intoxication with hyponatremia, (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, thiazide diuretics, NSAIDs, lamotrigine, sulfonylureas, particularly chlorpropamide, oxybutynin and carbamazepine). (label Desmopresin, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk [see Use in Specific Populations (8.5) and Clinical Pharmacology (12.3) ] . (label Desvenlafaksin, Peringatan dan perhatian)

The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (label Dietilpropion, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Serum potassium levels should be carefully monitored when digoxin is given to patients at high risk of hypokalemia ( e.g. , those receiving diuretics, corticosteroids, or other drugs that commonly lead to potassium loss; those with gastrointestinal losses through diarrhea, vomiting, or nasogastric suction; or those with potassium-losing endocrinopathies or nephropathies). (label Digoksin, Peringatan dan perhatian)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Risk may be increased when used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (label Dokserkalsiferol, Peringatan dan perhatian)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (label Drospirenon dan etinilestradiol, Peringatan dan perhatian)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (label Duloksetin, Peringatan dan perhatian)

Calcium Channel Antagonists Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (label Dutasterid, Interaksi obat)

Calcium Channel Antagonists Dutasteride Coadministration of verapamil or diltiazem decreases dutasteride clearance and leads to increased exposure to dutasteride. (label Dutasterid dan tamsulosin, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Transporters Use caution when concomitantly administering ALVAIZ and drugs that are substrates of OATP1B1 (e.g., atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, olmesartan, pitavastatin, pravastatin, rosuvastatin, repaglinide, rifampin, simvastatin acid, SN-38 [active metabolite of irinotecan], valsartan) or breast cancer resistance protein (BCRP)… (label Eltrombopag, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

…Precautions (5.6) and Adverse Reactions (6) ]. β-blockers, such as propranolol Cyclopropane or halogenated hydrocarbon anesthetics, such as halothane Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline… (label Epinefrin, Interaksi obat)

Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (label Epoetin alfa, Peringatan dan perhatian)

Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (label Epoprostenol, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Esitalopram, Peringatan dan perhatian)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (label Esomeprazol, Peringatan dan perhatian)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Drug Interactions with Amlodipine Simvastatin: Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

…hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (label Fenelzin, Peringatan)

Antagonistic Effects (decrease in BIORPHEN blood pressure effect) can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents. (label Fenilefrin, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

…treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte imbalance. (label Fentanil, Peringatan dan perhatian)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (label Fludrokortison, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Fluoksetin, Peringatan dan perhatian)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Diuretics: Use with caution. (label Flutikason dan salmeterol, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume depleted may be at greater risk. (label Fluvoksamin, Peringatan dan perhatian)

• Xanthine derivatives, steroids, diuretics, or non-potassium sparing diuretics may potentiate hypokalemia or ECG changes. (label Formoterol, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

When diuretics are indicated, thiazides are recommended over loop diuretics because the latter inhibit renal tubular secretion, and may impair elimination of FOSCAVIR, potentially leading to toxicity. (label Foskarnet, Interaksi obat)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

OATP1B1 substrates – Gemfibrozil is an inhibitor of organic anion-transporter polyprotein (OATP) 1B1 and may increase exposure of drugs that are substrates of OATP1B1 (e.g., atrasentan, atorvastatin, bosentan, ezetimibe, fluvastatin, glyburide, SN-38 [active metabolite of irinotecan], rosuvastatin, pitavastatin, pravastatin, rifampin, valsartan, olmesartan). (label Gemfibrozil, Peringatan)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (label Haloperidol, Interaksi obat)

Example: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Hidrokodon, Interaksi obat)

Diuretics : Hydrocodone may reduce the efficacy of diuretics. (label Hidrokodon dan homatropin, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Diuretics : Hydrocodone may reduce the efficacy of diuretics. (label Hidrokodon dan klorfeniramin, Interaksi obat)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Hidrokodon dan parasetamol, Interaksi obat)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Hidromorfon, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (label Iloperidon, Peringatan dan perhatian)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with imipramine hydrochloride tablets. (label Imipramin, Peringatan)

Drug Interactions Other Antihypertensives: Indapamide may add to or potentiate the action of other antihypertensive drugs. (label Indapamid, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Diuretics The electrocardiogram (ECG) changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by β-agonists, especially when the recommended dose of the β-agonist is exceeded. (label Ipratropium dan salbutamol, Interaksi obat)

Hypotension in Volume or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initialization of treatment with AVAPRO. (label Irbesartan, Peringatan dan perhatian)

Calcium Antagonists FORANE may lead to marked hypotension in patients treated with calcium antagonists. (label Isofluran, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Marked symptomatic orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used in combination. (label Isosorbid mononitrat, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (label Kalium iodida, Interaksi obat)

Thiazides Thiazides are known to induce hypercalcemia by the reduction of calcium excretion in urine. (label Kalsitriol, Interaksi obat)

Calcium Channel Blockers : Administration of calcium may reduce the response. (label Kalsium glukonat, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. (label Kandesartan, Peringatan dan perhatian)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (label Karbidopa, Interaksi obat)

Antihypertensive drugs: May cause symptomatic postural hypotension. (label Karbidopa dan levodopa, Interaksi obat)

Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (label Karbidopa, levodopa, dan entakapon, Interaksi obat)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (label Kariprazin, Peringatan dan perhatian)

If such symptoms occur, diuretics should be increased and the carvedilol dose should not be advanced until clinical stability resumes [see Dosage and Administration (2) ] . (label Karvedilol, Peringatan dan perhatian)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Consider use of diuretics and/or albumin. (label Klofarabin, Peringatan dan perhatian)

Drugs that affect sinus node function or AV node conduction (e.g., digitalis, calcium channel blockers, beta blockers) Clinical Implication Concomitant use of drugs that affect sinus node function or AV node conduction with clonidine potentiate bradycardia and risk of AV block [see Warnings and Precautions (5.1) ]. (label Klonidin, Interaksi obat)

Thiazides may add to or potentiate the action of other antihypertensive drugs. (label Klorotiazid, Peringatan)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (label Klorpromazin, Perhatian)

Effect of chlorthalidone on other drugs Chlorthalidone may add to or potentiate the action of other antihypertensive drugs. (label Klortalidon, Interaksi obat)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Kodein, Interaksi obat)

• Colesevelam hydrochloride: Consider administering olmesartan at least 4 hours before colesevelam hydrochloride dose. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Cholestyramine and colestipol: Reduced absorption of thiazides. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Cholestyramine and colestipol: Reduced absorption of thiazides. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (label Kuetiapin, Peringatan dan perhatian)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

Drugs that alkalinize the urine ( carbonic-anhydrase inhibitors, sodium bicarbonate, thiazide diuretics ) reduce renal elimination of quinidine. (label Kuinidin, Interaksi obat)

VIMPAT should also be used with caution in patients on concomitant medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval [see Drug Interactions (7.2) ] . (label Lakosamid, Peringatan dan perhatian)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ] . (label Lansoprazol, Peringatan dan perhatian)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume depleted can be at greater risk. (label Levomilnasipran, Peringatan dan perhatian)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Levorfanol, Interaksi obat)

Diuretics The ECG changes or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop and thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (label Levosalbutamol, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Monitor serum sodium levels regularly in the elderly, in patients taking diuretics, and in other patients at risk of hyponatremia and/or SIADH while taking Linezolid injection. (label Linezolid, Peringatan dan perhatian)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

• Lithium: Increases in serum lithium concentrations and lithium toxicity. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Weak CYP3A4 Inhibitors Weak CYP3A4 inhibitors (such as alprazolam, amiodarone, amlodipine, atorvastatin, bicalutamide, cilostazol, cimetidine, cyclosporine, fluoxetine, fluvoxamine, ginkgo, goldenseal, isoniazid, lapatinib, nilotinib, pazopanib, ranitidine, ranolazine, ticagrelor, zileuton) can increase lomitapide exposure approximately 2-fold [see Clinical Pharmacology… (label Lomitapid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. (label Losartan, Peringatan dan perhatian)

Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (label Lumateperon, Peringatan dan perhatian)

Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (label Lurasidon, Peringatan dan perhatian)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (label Meflokuin, Interaksi obat)

The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (label Mekamilamin, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Closely monitor patients with risk factors for development of prolonged QT interval (e.g., cardiac hypertrophy, concomitant diuretic use, hypokalemia, hypomagnesemia), a history of cardiac conduction abnormalities, and those taking medications affecting cardiac conduction. (label Metadon, Peringatan dan perhatian)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Antihypertensive Drugs: Monitor blood pressure. (label Metilfenidat, Interaksi obat)

If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of Metoprolol Tartrate Tablets [see Dosage and Administration (2) ]. (label Metoprolol, Peringatan dan perhatian)

Digitalis, Clonidine, and Calcium Channel Blockers: Digitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction and decrease heart rate. (label Metoprolol dan hidroklorotiazid, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Geriatric Use ( 8.5 )] . (label Milnasipran, Peringatan dan perhatian)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia [see Use in Specific Populations (8.5) ] . (label Mirtazapin, Peringatan dan perhatian)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Morfin, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Although beta-blockers should be avoided in overt congestive heart failure, if necessary, they can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. (label Nadolol, Peringatan)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Nalbufin, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Increase the dose of diuretics as needed [see Adverse Reactions (6) ] . (label Natrium zirkonium siklosilikat, Peringatan dan perhatian)

Non-dihydropyridine Calcium Channel Blockers Because of significant negative inotropic and chronotropic effects in patients treated with β-blockers and calcium channel blockers of the verapamil and diltiazem type, monitor the ECG and blood pressure in patients treated concomitantly with these agents. (label Nebivolol, Peringatan dan perhatian)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Caution should also be used when niacin extended-release tablets are used in patients with unstable angina or in the acute phase of an MI, particularly when such patients are also receiving vasoactive drugs such as nitrates, calcium channel blockers, or adrenergic blocking agents. (label Niasin, Peringatan dan perhatian)

Other Diuretics, PDE5 inhibitors, alpha-methyldopa: Nifedipine may increase the blood pressure lowering effect of these concomitantly administered agents. (label Nifedipin, Interaksi obat)

Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (label Nimodipin, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Antihypertensives: Possible additive hypotensive effects. (label Nitrogliserin, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Oksikodon, Interaksi obat)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Oksikodon dan parasetamol, Interaksi obat)

Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Oksimorfon, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Beta Blocker and Calcium Channel Blockers : dose adjustment of beta blockers or calcium channel blockers may be necessary (‎ 7 ). (label Oktreotid, Interaksi obat)

…of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (label Olanzapin, Peringatan dan perhatian)

…and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (label Olanzapin dan fluoksetin, Peringatan dan perhatian)

Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Oliseridin, Interaksi obat)

Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin-aldosterone system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may be anticipated after initiation of treatment with Benicar. (label Olmesartan, Peringatan dan perhatian)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (label Omeprazol, Peringatan dan perhatian)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions ( 6.2 )] . (label Omeprazol dan natrium bikarbonat, Peringatan dan perhatian)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (label Paliperidon, Peringatan dan perhatian)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (label Pantoprazol, Peringatan dan perhatian)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Parasetamol dan kodein, Interaksi obat)

The risk may be increased when Paricalcitol Injection is used concomitantly with high dose calcium preparations, thiazide diuretics, or vitamin D compounds. (label Parikalsitol, Peringatan dan perhatian)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SNRIs and SSRIs. [see Use in Specific Populations ( 8.5 )]. (label Paroksetin, Peringatan dan perhatian)

Adjustments in the dose of drugs known to slow the heart rate (e.g., beta-blockers, calcium channel blockers) and correction of electrolyte disturbances may be necessary when initiating or during the course of SIGNIFOR LAR treatment. (label Pasireotid, Peringatan dan perhatian)

Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (label Pazopanib, Peringatan dan perhatian)

Diuretics Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Pentazosin dan nalokson, Interaksi obat)

Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (label Pentoksifilin, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

Examples: Cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Petidin, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Although beta-blockers should be avoided in overt congestive heart failure, if necessary, pindolol tablets can be used with caution in patients with a history of failure who are well-compensated, usually with digitalis and diuretics. (label Pindolol, Peringatan)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (label Prazosin, Peringatan)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (label Proklorperazin, Perhatian)

Diuretics : Codeine may reduce the efficacy of diuretics. (label Prometazin dan kodein, Interaksi obat)

The concomitant use of beta-adrenergic blockers and non-dihydropyridine calcium channel blockers (e.g., verapamil and diltiazem), digoxin or clonidine increases the risk of significant bradycardia. (label Propranolol, Peringatan dan perhatian)

For patients expected to be on prolonged treatment or who take PPIs with medications such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), health care professionals may consider monitoring magnesium levels prior to initiation of PPI treatment and periodically [see Adverse Reactions (6.2) ]. (label Rabeprazol, Peringatan dan perhatian)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (label Riosiguat, Peringatan dan perhatian)

Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (label Risperidon, Peringatan dan perhatian)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), are at greater risk. (label Sakubitril dan valsartan, Peringatan dan perhatian)

Diuretics: Use with caution. (label Salbutamol, Interaksi obat)

• Diuretics: Use with caution. (label Salmeterol, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Diuretics: Nephrotoxicity has been reported with concomitant administration of cephalosporins with potent diuretics such as furosemide. (label Sefepim, Interaksi obat)

Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. (label Seftazidim, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (label Sertralin, Peringatan dan perhatian)

Calcium antagonists Sevoflurane may lead to marked hypotension in patients treated with calcium antagonists. (label Sevofluran, Interaksi obat)

…concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (label Siklobenzaprin, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

When amlodipine, 5 mg or 10 mg, and sildenafil 100 mg were orally administered concomitantly to hypertensive patients, mean additional blood pressure reductions of 8 mmHg systolic and 7 mmHg diastolic were noted [see Drug Interactions ( 7.3 ) and Clinical Pharmacology ( 12.2 ) ]. (label Sildenafil, Peringatan dan perhatian)

However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (label Silodosin, Peringatan dan perhatian)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Drug Interactions with Amlodipine Simvastatin: Co-administration of simvastatin with amlodipine increases the systemic exposure of simvastatin. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Elderly patients, patients taking diuretics, and those who are volume depleted may be at greater risk for developing hyponatremia with SSRIs [see Use in Specific Populations ( 8.5 )] . (label Sitalopram, Peringatan dan perhatian)

Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (label Sorafenib, Peringatan dan perhatian)

Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs. (label Sotalol, Peringatan dan perhatian)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

Prolonged Neuromuscular Block in Patients with Hypokalemia or Hypocalcemia Neuromuscular blockade may be prolonged in patients with hypokalemia (e.g., after severe vomiting, diarrhea, digitalisation and diuretic therapy) or hypocalcemia (e.g., after massive transfusions). (label Suksinilkolin, Peringatan dan perhatian)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Initiate and/or adjust antihypertensive therapy as appropriate. (label Sunitinib, Peringatan dan perhatian)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

• Increased exposure to cyclosporin and tacrolimus. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

…use of skeletal muscle relaxants and opioids, consider prescribing naloxone for the emergency treatment of opioid overdose [see Dosage and Administration (2.2) , Warnings and Precautions (5.2 , 5.3) ] Examples: cyclobenzaprine, metaxalone Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Tapentadol, Interaksi obat)

Hypotension In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of therapy with telmisartan tablets. (label Telmisartan, Peringatan dan perhatian)

Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. (label Telmisartan dan amlodipin, Interaksi obat)

…Metabolic Disorders Drugs, including telmisartan, that inhibit the renin-angiotensin system can cause hyperkalemia, particularly in patients with renal insufficiency, diabetes, or combination use with other angiotensin receptor blockers or ACE inhibitors and the concomitant use of other drugs that raise serum potassium levels [see Drug Interactions (7.1 , 7.4) ] . (label Telmisartan dan hidroklorotiazid, Peringatan dan perhatian)

Monitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine). (label Temsirolimus, Interaksi obat)

Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (label Terazosin, Peringatan dan perhatian)

Diuretics The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. (label Terbutalin, Perhatian)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (label Testosteron, Peringatan dan perhatian)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Oral or intravenous calcium antagonists may cause atrioventricular conduction disturbances, left ventricular failure, and hypotension. (label Timolol, Interaksi obat)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. (label Tobramisin, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Olmesartan medoxomil ( 7.1 ): • Nonsteroidal anti-inflammatory drugs (NSAIDS): May lead to increased risk of renal impairment and loss of antihypertensive effect. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Co-administration of diuretics also increases the risk of too rapid correction of serum sodium and such patients should undergo close monitoring of serum sodium. (label Tolvaptan, Peringatan dan perhatian)

Blood pressure should be closely monitored when amlodipine is co-administered with CYP3A inducers. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

Drugs that decrease renal calcium excretion, e.g., thiazide diuretics, may increase the risk of hypercalcemia in patients receiving FARESTON. (label Toremifen, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Tramadol, Interaksi obat)

Diuretics Clinical Impact: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. (label Tramadol dan parasetamol, Interaksi obat)

In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen (BUN) have been reported. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (label Trazodon, Peringatan dan perhatian)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics) symptomatic hypotension may be anticipated after initiation of treatment with olmesartan medoxomil. (label Olmesartan, amlodipin, dan hidroklorotiazid, Peringatan dan perhatian)

Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. (label Trifluoperazin, Perhatian)

• Diuretics: Use with caution. (label Umeklidinium dan vilanterol, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Immunosuppressants: Amlodipine may increase the systemic exposure of cyclosporine or tacrolimus when co-administered. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients receiving high doses of diuretics, symptomatic hypotension may occur. (label Valsartan, Peringatan dan perhatian)

Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (label Vardenafil, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted may be at greater risk [see Use in Specific Populations ( 8.5 )] . (label Venlafaksin, Peringatan dan perhatian)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Elderly patients, patients taking diuretics, and those who are volume-depleted may be at greater risk of developing hyponatremia with SSRIs and SNRIs [see Use in Specific Populations ( 8.5 )] . (label Vilazodon, Peringatan dan perhatian)

Diuretik tiazid mengurangi ekskresi kalsium; bila dikombinasikan dengan suplemen vitamin D dan kalsium, hal ini dapat berujung pada hiperkalsemia, terutama pada orang lanjut usia. (NIH Office of Dietary Supplements, Vitamin D)

• Increased amlodipine exposure when coadministered with CYP3A inhibitors Hydrochlorothiazide ( 7.3 ): • Antidiabetic drugs: Dosage adjustment of antidiabetic may be required. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Also, patients taking diuretics or who are otherwise volume-depleted can be at greater risk. (label Vortioksetin, Peringatan dan perhatian)

…propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, zileuton montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem,… (label Warfarin, Interaksi obat)

Hypokalemia may result from diuretic therapy, diarrhea, and other causes. (label Ziprasidon, Peringatan dan perhatian)

Effects of Adenosine on Other Drugs Adenosine injection has been given with other cardioactive drugs (such as beta adrenergic blocking agents, cardiac glycosides, and calcium channel blockers) without apparent adverse interactions, but its effectiveness with these agents has not been systematically evaluated. (label Adenosin, Interaksi obat)

Coadministration of 1 Dyazide (triamterene/hydrochlorothiazide) resulted in a higher plasma amantadine hydrochloride concentration in a 61-year old man receiving amantadine hydrochloride 100 mg TID for Parkinson's disease. (label Amantadin, Interaksi obat)

Patients required intervention with a diuretic, fluid management, or, in some cases, hospitalization for decompensating heart failure. (label Ambrisentan, Peringatan dan perhatian)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (label Butorfanol, Peringatan)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (label Dasatinib, Peringatan dan perhatian)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Examples of alkalinizing agents include gastrointestinal alkalinizing agents (e.g., sodium bicarbonate) and urinary alkalinizing agents (e.g. acetazolamide, some thiazides). (label Dekstroamfetamin, Interaksi obat)

…malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants. [see Contraindications (4), Clinical Pharmacology (12.5)] Signs consistent with malignant hyperthermia may include hyperthermia, hypoxia,… (label Desfluran, Peringatan dan perhatian)

If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (label Desogestrel dan etinilestradiol, Peringatan)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Patients developing peripheral edema may be treated with standard measures, e.g., salt restriction, oral diuretic(s). (label Dosetaksel, Peringatan dan perhatian)

Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (label Efedrin, Interaksi obat)

In addition to discontinuation of the drug, diuretic therapy may be required. (label Estrogen teresterifikasi dan metiltestosteron, Peringatan)

In Vivo Drug Interaction Studies Based on drug interaction studies in healthy patients, ULORIC does not have clinically significant interactions with colchicine, naproxen, indomethacin, hydrochlorothiazide, warfarin or desipramine [see Clinical Pharmacology (12.3) ]. (label Febuksostat, Interaksi obat)

…studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), benzodiazepines, H 2 antagonists and quinolone anti-infectives… (label Finasterid, Interaksi obat)

Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. (label Flekainid, Interaksi obat)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (label Hidralazin, Interaksi obat)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (label Ikatibant, Interaksi obat)

Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of isradipine and hydrochlorothiazide does not result in altered pharmacokinetics of either drug. (label Isradipin, Interaksi obat)

Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (label Kalium klorida, Interaksi obat)

Diuretik tiazid mengurangi ekskresi kalsium, sehingga asupan kalsium yang tinggi dapat menaikkan kalsium darah. (NIH Office of Dietary Supplements, Calcium)

Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. (label Kandesartan dan hidroklorotiazid, Peringatan)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Acthar Gel may accentuate the electrolyte loss associated with diuretic therapy. (label Kortikotropin, Interaksi obat)

Penggunaan jangka panjang diuretik loop dan diuretik tiazid meningkatkan kehilangan magnesium melalui urine. (NIH Office of Dietary Supplements, Magnesium)

Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported [see Adverse Reactions (6.2) ] . (label Masitentan, Peringatan dan perhatian)

In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (label Meksiletin, Interaksi obat)

Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (label Metildopa, Interaksi obat)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

In addition to discontinuation of the drug, diuretic therapy may be required. (label Metiltestosteron, Peringatan)

…been observed in limited experience with patients in whom milrinone was used concurrently with the following drugs: digitalis glycosides; lidocaine, quinidine; hydralazine, prazosin; isosorbide dinitrate, nitroglycerin; chlorthalidone, furosemide, hydrochlorothiazide, spironolactone; captopril; heparin, warfarin, diazepam, insulin; and potassium supplements. (label Milrinon, Interaksi obat)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (label Nisoldipin, Interaksi obat)

Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (label Nitroprusid, Peringatan)

The antihypertensive action of guanethidine and similar agents may be blocked. (label Nortriptilin, Peringatan)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (label Protriptilin, Peringatan)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers. (label Terbinafin, Interaksi obat)

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. (label Olmesartan, amlodipin, dan hidroklorotiazid, Interaksi obat)

No other formal drug-drug interaction studies between zafirlukast and marketed drugs known to be metabolized by the P450 3A4 (CYP3A4) isoenzyme (e.g., dihydropyridine calcium-channel blockers, cyclosporin, cisapride) have been conducted. (label Zafirlukast, Perhatian)

Diuretik tiazid meningkatkan kehilangan zink melalui urine pada penggunaan jangka panjang. (NIH Office of Dietary Supplements, Zinc)

Calcium channel blocking agents: Coadministration of calcium channel blockers did not have any effect on either the safety or efficacy of ibutilide in the clinical trials. (label Ibutilid, Interaksi obat)

Loop Diuretics Concomitant administration of a loop diuretic had no effect on the calcium-lowering action of pamidronate disodium. (label Pamidronat, Interaksi obat)

Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (label Ropinirol, Interaksi obat)